Use of tocolytics: what is the benefit of gaining 48 hours for the fetus?
Preterm birth remains one of the serious problems in perinatal medicine and is associated with an increased risk of neonatal complications and long-term morbidity. Although each day that delivery is delayed between 22 and 28 weeks of gestation increases survival by 3%, since most spontaneous preterm labour occurs between 28 and 34 weeks of gestation, this is of secondary concern; the primary goal of delay is to improve the function of certain systems in the fetus and to balance the risks of a hostile intrauterine environment with the complications of extrauterine preterm life. Although there is a lack of definitive evidence that tocolytic drugs improve outcome following spontaneous preterm labour and preterm birth, there is ample evidence that tocolysis delays delivery for long enough to permit administration of a complete course of antepartum glucocorticoids and to facilitate in utero transfer to a tertiary care unit where neonatal care will be optimal. Both these measures have been associated with improved outcomes; antepartum glucocorticoids reduce the incidence of respiratory distress syndrome, intraventricular haemorrhage, periventricular leucomalacia and necrotising enterocolitis, and in utero transfer is associated with decreased morbidity and mortality and less hospital-based intervention compared with postnatal transportation. Consequently, women who are more likely to benefit from tocolysis are those at early gestational ages, those needing transfer to a hospital that can provide neonatal intensive care and those who have not yet received a full course of antepartum glucocorticosteroids. In these cases, delaying labour for at least 48 hours with drugs such as atosiban should be considered, since it offers clear advantages for the fetus.
Di Renzo
G C
GC
Department of Gynaecology and Obstetrics, Centre of Reproductive and Perinatal Medicine, University of Perugia, Policlinico Monteluce, Perugia, Italy. direnzo@unipg.it
Al Saleh
E
E
Mattei
A
A
Koutras
I
I
Clerici
G
G
D005260:Female; D047109:Fetal Development / Q000187:drug effects*; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D015931:Intensive Care, Neonatal; D007752:Obstetric Labor, Premature / Q000188:drug therapy*; D010360:Patient Transfer; D011247:Pregnancy; D011256:Pregnancy Outcome; D015149:Tocolytic Agents / Q000627:therapeutic use*
D005938:Glucocorticoids; D015149:Tocolytic Agents